[Rufinamide. A review of its pharmacokinetic and pharmacodynamic properties].
OBJECTIVE
To review the most important research published on the pharmacokinetic and pharmacodynamic properties of rufinamide (RFM), together with the outcomes of the clinical trials conducted to date with this new antiepileptic drug.


METHODS
RFM is a triazole derivative with no structural relation to the other antiepileptic drugs, and the effectiveness and safety profiles shown in laboratory animals suggest that it could be effective in the treatment of partial and generalised seizures. In fact, in double-blind trials RFM has proved to be effective and well tolerated in adults with intractable partial seizures and in patients between 4 and 30 years of age with Lennox-Gastaut syndrome.


CONCLUSIONS
Based on the results of clinical trials, RFM has been approved in the European Union for specific use in patients with Lennox-Gastaut syndrome and therefore represents a new therapeutic alternative with which to offset the medication resistance of this epileptic encephalopathy.
Servicio de Neuropediatria, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, España. pedhfj@humv.es
J L
JL
Herranz
D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D015394:Molecular Structure; D013577:Syndrome; D014230:Triazoles / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000927:Anticonvulsants; D014230:Triazoles; C079703:rufinamide
Rufinamida. Revisión de sus propiedadesfarmacocinéticas y farmacodinámicas.